A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

• Multiple Outcomes of Raloxifene Evaluation (MORE), a placebo controlled phase III study of raloxifene in postmenopausal osteoporosis, showed that both doses tested (60 mg and 120 mg daily) reduced the risk of vertebral fracture. There was no significant effect on non-vertebral fracture.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

epidemiology

Spinal Fractures

Placebos

Humans

Incidence

Proportional Hazards Models

therapeutic use

Algorithms

therapeutic use

epidemiology

Osteoporotic Fractures

80 and over

drug therapy

Risk Factors

Middle Aged

Treatment Outcome

Female

Adult

Aged

drug therapy

Raloxifene

Aged

Bone Density Conservation Agents

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)